{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T15:52:36Z","timestamp":1792511556794,"version":"4.5.0"},"reference-count":44,"publisher":"Elsevier BV","issue":"14","license":[{"start":{"date-parts":[[2017,10,1]],"date-time":"2017-10-01T00:00:00Z","timestamp":1506816000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,10,1]],"date-time":"2017-10-01T00:00:00Z","timestamp":1506816000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2018,10,3]],"date-time":"2018-10-03T00:00:00Z","timestamp":1538524800000},"content-version":"vor","delay-in-days":367,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American College of Cardiology"],"published-print":{"date-parts":[[2017,10]]},"DOI":"10.1016\/j.jacc.2017.08.038","type":"journal-article","created":{"date-parts":[[2017,9,25]],"date-time":"2017-09-25T16:16:08Z","timestamp":1506356168000},"page":"1777-1784","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":158,"title":["The Clinical Use of Ivabradine"],"prefix":"10.1016","volume":"70","author":[{"given":"Jacob S.","family":"Koruth","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anuradha","family":"Lala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean","family":"Pinney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivek Y.","family":"Reddy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Srinivas R.","family":"Dukkipati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jacc.2017.08.038_bib1","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.pharmthera.2005.01.005","article-title":"Physiology and pharmacology of the cardiac pacemaker (\u201cfunny\u201d) current","volume":"107","author":"Baruscotti","year":"2005","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.jacc.2017.08.038_bib2","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/S0022-3565(25)12114-9","article-title":"Coronary and hemodynamic effects of S 16257, a new bradycardic agent, in resting and exercising conscious dogs","volume":"275","author":"Simon","year":"1995","journal-title":"J\u00a0Pharmacol Exp Ther"},{"key":"10.1016\/j.jacc.2017.08.038_bib3","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1097\/00005344-200311000-00016","article-title":"Anti-ischemic effects of ivabradine, a selective heart rate-reducing agent, in exercise-induced myocardial ischemia in pigs","volume":"42","author":"Vilaine","year":"2003","journal-title":"J\u00a0Cardiovasc Pharmacol"},{"key":"10.1016\/j.jacc.2017.08.038_bib4","first-page":"3291","article-title":"Bradycardia and atrial fibrillation in patients with stable coronary artery disease treated with ivabradine: an analysis from the SIGNIFY study","volume":"36","author":"Fox","year":"2015","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2017.08.038_bib5","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1136\/heartjnl-2014-305482","article-title":"Atrial fibrillation associated with ivabradine treatment: meta-analysis of randomised controlled trials","volume":"100","author":"Martin","year":"2014","journal-title":"Heart"},{"key":"10.1016\/j.jacc.2017.08.038_bib6","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1007\/s12012-014-9274-y","article-title":"Torsades de pointes induced by the concomitant use of ivabradine and azithromycin: an unexpected dangerous interaction","volume":"15","author":"Cocco","year":"2015","journal-title":"Cardiovasc Toxicol"},{"key":"10.1016\/j.jacc.2017.08.038_bib7","unstructured":"European Database of Suspected Adverse Drug Reaction Reports. European Medicines Agency. 2016. Available at: http:\/\/www.adrreports.eu\/en\/index.html. Accessed August 17,\u00a02017."},{"key":"10.1016\/j.jacc.2017.08.038_bib8","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.yjmcc.2015.05.009","article-title":"Ivabradine prolongs phase 3 of cardiac repolarization and blocks the hERG1 (KCNH2) current over a concentration-range overlapping with that required to block HCNs","volume":"85","author":"Lees-Miller","year":"2015","journal-title":"J\u00a0Mol Cell Cardiol"},{"key":"10.1016\/j.jacc.2017.08.038_bib9","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1016\/S0140-6736(10)61198-1","article-title":"Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study","volume":"376","author":"Swedberg","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2017.08.038_bib10","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1016\/S0140-6736(10)61259-7","article-title":"Heart rate as a risk factor in chronic heart failure (SHIFT): the association between heart rate and outcomes in a randomised placebo-controlled trial","volume":"376","author":"B\u00f6hm","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2017.08.038_bib11","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1161\/01.CIR.0000048143.25023.87","article-title":"Antianginal and antiischemiceffects of ivabradine, an If inhibitor, in stable angina: a randomized, double-blind, multicentered, placebo-controlled trial","volume":"107","author":"Borer","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2017.08.038_bib12","doi-asserted-by":"crossref","first-page":"2529","DOI":"10.1093\/eurheartj\/ehi586","article-title":"Efficacy of ivabradine, a new selective If inhibitor, compared with atenolol in patients with chronic stable angina","volume":"26","author":"Tardif","year":"2005","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2017.08.038_bib13","doi-asserted-by":"crossref","first-page":"393","DOI":"10.2165\/00003495-200767030-00005","article-title":"Antianginal efficacy and safety of ivabradine compared with amlodipine in patients with stable effort angina pectoris: a 4-month randomized, double-blind, multicenter, noninferiority trial","volume":"67","author":"Ruzyllo","year":"2007","journal-title":"Drugs"},{"key":"10.1016\/j.jacc.2017.08.038_bib14","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1093\/eurheartj\/ehn571","article-title":"Efficacy of the If current inhibitor ivabradine in patients with chronic stable angina receiving beta-blocker therapy: a 4-month, randomized, placebo-controlled trial","volume":"30","author":"Tardif","year":"2009","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2017.08.038_bib15","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1007\/s00392-011-0402-4","article-title":"Ivabradine in combination with beta-blocker improves symptoms and quality of life in patients with stable angina pectoris: results from the ADDITIONS study","volume":"101","author":"Werdan","year":"2012","journal-title":"Clin Res Cardiol"},{"key":"10.1016\/j.jacc.2017.08.038_bib16","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1016\/S0140-6736(08)61170-8","article-title":"Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial","volume":"372","author":"Fox","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2017.08.038_bib17","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/S0140-6736(08)61171-X","article-title":"Heart rate as a prognostic risk factor in patients with coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a subgroup analysis of a randomised controlled trial","volume":"372","author":"Fox","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2017.08.038_bib18","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1056\/NEJMoa1406430","article-title":"Ivabradine in stable coronary artery disease without clinical heart failure","volume":"371","author":"Fox","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2017.08.038_bib19","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.1093\/eurheartj\/ehp358","article-title":"Relationship between ivabradine treatment and cardiovascular outcomes in patients with stable coronary artery disease and left ventricular systolic dysfunction with limiting angina: A subgroup analysis of the randomized, controlled BEAUTIFUL trial","volume":"30","author":"Fox","year":"2009","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2017.08.038_bib20","doi-asserted-by":"crossref","first-page":"2949","DOI":"10.1093\/eurheartj\/eht296","article-title":"2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the Management of Stable Coronary Artery Disease of the European Society of Cardiology","volume":"34","author":"Montalescot","year":"2013","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2017.08.038_bib21","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1001\/jama.283.10.1295","article-title":"Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: the Metoprolol CR\/XL Randomized Intervention Trial in congestive heart failure (MERIT-HF)","volume":"283","author":"Hjalmarson","year":"2000","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2017.08.038_bib22","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0140-6736(03)13800-7","article-title":"Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial","volume":"362","author":"Poole-Wilson","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2017.08.038_bib23","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.jacc.2008.04.028","article-title":"Predictors of in-hospital mortality in patients hospitalized for heart failure: insights from the Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF)","volume":"52","author":"Abraham","year":"2008","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2017.08.038_bib24","doi-asserted-by":"crossref","first-page":"1890","DOI":"10.1016\/j.amjcard.2015.09.029","article-title":"Influence of cardiovascular and noncardiovascular co-morbidities on outcomes and treatment effect of heart rate reduction with ivabradine in stable heart failure (from the SHIFT Trial)","volume":"116","author":"B\u00f6hm","year":"2015","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacc.2017.08.038_bib25","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1002\/ejhf.347","article-title":"Efficacy and safety of ivabradine in patients with chronic systolic heart failure and diabetes: an analysis from the SHIFT trial","volume":"17","author":"Komajda","year":"2015","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jacc.2017.08.038_bib26","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1002\/ejhf.59","article-title":"The effect of heart rate reduction with ivabradine on renal function in patients with chronic heart failure: an analysis from SHIFT","volume":"16","author":"Voors","year":"2014","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jacc.2017.08.038_bib27","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.ijcard.2013.10.068","article-title":"Clinical profiles and outcomes in patients with chronic heart failure and chronic obstructive pulmonary disease: an efficacy and safety analysis of SHIFT study","volume":"170","author":"Tavazzi","year":"2013","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.jacc.2017.08.038_bib28","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1016\/j.jacc.2017.04.025","volume":"70","author":"Yancy","year":"2017","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2017.08.038_bib29","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1002\/ejhf.592","volume":"18","author":"Ponikowski","year":"2016","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jacc.2017.08.038_bib30","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.ijcard.2016.04.136","article-title":"Effect of early treatment with ivabradine combined with beta-blockers versus beta-blockers alone in patients hospitalised with heart failure and reduced left ventricular ejection fraction (ETHIC-AHF): a randomised study","volume":"217","author":"Hidalgo","year":"2016","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.jacc.2017.08.038_bib31","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1016\/j.jacc.2008.06.048","article-title":"Relation of beta-blocker-induced heart rate lowering and cardioprotection in hypertension","volume":"52","author":"Bangalore","year":"2008","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2017.08.038_bib32","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1159\/000322905","article-title":"Heart rate reduction by ivabradine reduces diastolic dysfunction and cardiac fibrosis","volume":"117","author":"Busseuil","year":"2010","journal-title":"Cardiology"},{"key":"10.1016\/j.jacc.2017.08.038_bib33","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1016\/j.jacc.2013.06.043","article-title":"Effect of If-channel inhibition on hemodynamic status and exercise tolerance in heart failure with preserved ejection fraction: a randomized trial","volume":"62","author":"Kosmala","year":"2013","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2017.08.038_bib34","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1161\/CIRCULATIONAHA.115.017119","article-title":"Effect of selective heart rate slowing in heart failure with preserved ejection fraction","volume":"132","author":"Pal","year":"2015","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2017.08.038_bib35","doi-asserted-by":"crossref","DOI":"10.1002\/ejhf.876","article-title":"Effect of ivabradine in patients with heart failure with preserved ejection fraction: the EDIFY randomized placebo-controlled trial","author":"Komajda","year":"2017","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jacc.2017.08.038_bib36","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1159\/000111931","article-title":"Ivabradine as an alternative therapeutic trial in the treatment of inappropriate sinus tachycardia: a case report","volume":"110","author":"Schulze","year":"2008","journal-title":"Cardiology"},{"key":"10.1016\/j.jacc.2017.08.038_bib37","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1016\/j.hrthm.2010.05.034","article-title":"Efficacy of ivabradine administration in patients affected by inappropriate sinus tachycardia","volume":"7","author":"Cal\u00f2","year":"2010","journal-title":"Heart Rhythm"},{"key":"10.1016\/j.jacc.2017.08.038_bib38","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1093\/europace\/eus204","article-title":"Metoprolol succinate vs. ivabradine in the treatment of inappropriate sinus tachycardia in patients unresponsive to previous pharmacological therapy","volume":"15","author":"Ptaszynski","year":"2013","journal-title":"Europace"},{"key":"10.1016\/j.jacc.2017.08.038_bib39","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1016\/j.jacc.2012.06.031","article-title":"Clinical efficacy of ivabradine in patients with inappropriate sinus tachycardia: a prospective, randomized, placebo-controlled, double-blind, crossover evaluation","volume":"60","author":"Cappato","year":"2012","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2017.08.038_bib40","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/j.jacc.2017.03.002","article-title":"2017 ACC\/AHA\/HRS guideline for the evaluation and management of patients with syncope: executive summary: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines, and the Heart Rhythm Society","volume":"70","author":"Shen","year":"2017","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2017.08.038_bib41","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1093\/europace\/euq390","article-title":"Single centre experience of ivabradine in postural orthostatic tachycardia syndrome","volume":"13","author":"McDonald","year":"2011","journal-title":"Europace"},{"key":"10.1016\/j.jacc.2017.08.038_bib42","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1093\/europace\/euq497","article-title":"Ivabradine in the treatment of orthostatic intolerance","volume":"13","author":"Sutton","year":"2011","journal-title":"Europace"},{"key":"10.1016\/j.jacc.2017.08.038_bib43","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1016\/j.hrthm.2016.03.015","article-title":"Adjunctive ivabradine in combination with amiodarone: a novel therapy for pediatric congenital junctional ectopic tachycardia","volume":"13","author":"Dieks","year":"2016","journal-title":"Heart Rhythm"},{"key":"10.1016\/j.jacc.2017.08.038_bib44","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1111\/pace.12018","article-title":"Ivabradine in the treatment of inappropriate sinus tachycardia in patients after successful radiofrequency catheter ablation of atrioventricular node slow pathway","volume":"36","author":"Ptaszynski","year":"2013","journal-title":"Pacing Clin Electrophysiol"}],"container-title":["Journal of the American College of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735109717393464?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735109717393464?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T13:13:31Z","timestamp":1760015611000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0735109717393464"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10]]},"references-count":44,"journal-issue":{"issue":"14","published-print":{"date-parts":[[2017,10]]}},"alternative-id":["S0735109717393464"],"URL":"https:\/\/doi.org\/10.1016\/j.jacc.2017.08.038","relation":{},"ISSN":["0735-1097"],"issn-type":[{"value":"0735-1097","type":"print"}],"subject":[],"published":{"date-parts":[[2017,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Clinical Use of Ivabradine","name":"articletitle","label":"Article Title"},{"value":"Journal of the American College of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacc.2017.08.038","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 by the American College of Cardiology Foundation. Published by Elsevier.","name":"copyright","label":"Copyright"}]}}